SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/307345"
 

Search: onr:"swepub:oai:gup.ub.gu.se/307345" > Effectiveness and t...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005440naa a2200733 4500
001oai:gup.ub.gu.se/307345
003SwePub
008240910s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:147964747
024a https://gup.ub.gu.se/publication/3073452 URI
024a https://doi.org/10.1136/annrheumdis-2021-2200972 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1479647472 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Lindström, Ulfu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xlulfn
2451 0a Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
264 c 2021-06-03
264 1b BMJ,c 2021
520 a Background: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed. Results: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept. Conclusion: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a arthritis
653 a methotrexate
653 a psoriatic
653 a tumour necrosis factor inhibitors
700a Di Giuseppe, D.u Karolinska Institutet4 aut
700a Delcoigne, B.u Karolinska Institutet4 aut
700a Glintborg, B.4 aut
700a Möller, B.4 aut
700a Ciurea, A.4 aut
700a Pombo-Suarez, M.4 aut
700a Sanchez-Piedra, C.4 aut
700a Eklund, K.4 aut
700a Relas, H.4 aut
700a Gudbjornsson, B.4 aut
700a Love, T. J.4 aut
700a Jones, G. T.4 aut
700a Codreanu, C.4 aut
700a Ionescu, R.4 aut
700a Nekvindova, L.4 aut
700a Závada, J.4 aut
700a Atas, N.4 aut
700a Yolbas, S.4 aut
700a Fagerli, K. M.4 aut
700a Michelsen, B.4 aut
700a Rotar,, Rotar,4 aut
700a Tomšič, M.4 aut
700a Iannone, F.4 aut
700a Santos, M. J.4 aut
700a Avila-Ribeiro, P.4 aut
700a Ørnbjerg, L. M.4 aut
700a Østergaard, M.4 aut
700a Jacobsson, Lennart T. H.,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xjacle
700a Askling, J.u Karolinska Institutet4 aut
700a Nissen, M. J.4 aut
710a Göteborgs universitetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org
773t Annals of the Rheumatic Diseasesd : BMJg 80, s. 1410-1418q 80<1410-1418x 0003-4967x 1468-2060
856u https://ard.bmj.com/content/annrheumdis/early/2021/06/14/annrheumdis-2021-220097.full.pdf
8564 8u https://gup.ub.gu.se/publication/307345
8564 8u https://doi.org/10.1136/annrheumdis-2021-220097
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:147964747

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view